News Board

On June 10, 2026, Judge Valerie Figueredo, United States Magistrate Judge in the United States District Court for the Southern District of New York, signed an order consolidating recent class actions filed on behalf of shareholders of Coty Inc. who were harmed by alleged securities fraud. The consolidated case is captioned In re Coty Inc....Read more

Regencell told investors it was developing traditional Chinese medicine treatments for ADHD and autism. A tiny company with just 12 employees, no approved or salable products, no revenue, and a claimed TCM formula aimed at treating the fundamental cause of ADHD and autism. Then, according to the complaint, the stock went wild. According to the...Read more

Globant told investors Latin America was its next big success story. A $1 billion expansion. Strong demand. Rapid growth. A rising footprint across Brazil, Mexico, and Argentina. But shareholders allege the reality looked very different. The lawsuit says Globant was actually facing declining demand, canceled projects, and clients walking away. In Brazil, its big acquisition...Read more

LKQ told investors its $2.1 billion Uni-Select deal, including FinishMaster, would drive growth and strengthen its market position. According to the complaint, LKQ called it a “compelling strategic fit” with minimal integration risk. But the lawsuit says, FinishMaster was already losing major customers and market share. Investors allegedly had no idea. In February 2023, LKQ...Read more

Babcock & Wilcox told investors it had landed a transformational AI data center power deal worth over $1.5 billion. Then that story got even bigger, with executives raising it to a $2.4 billion contract and pointing to backlog and demand. But investors later learned allegations that cast the deal in a very different light. In...Read more

United Homes told investors it was exploring “strategic alternatives” to maximize shareholder value. It sounded disciplined. Thoughtful. Even shareholder friendly. But the complaint says something else was allegedly happening behind that review. In May 2025, United Homes launched that review and said every option was on the table. By August, executives were still talking about...Read more

Medpace told investors cancellations were “well behaved” and a 1.15 book to bill was still in reach. Growth looked steady. Backlog looked strong. Confidence stayed high. But behind the scenes, that optimism was hiding a different story. Throughout April, July, and October 2025, executives kept repeating that cancellations were under control and that the second...Read more

Stellantis told investors 2025 would be the year growth came back. Electrification was “growing,” margins were supposed to recover, and management said the company was built to win that shift. But behind the scenes, the complaint says Stellantis had badly misread EV demand and wasn’t positioned to turn that push into real profit. In February...Read more

Upstart told investors its AI was getting smarter. Model 22 was supposed to approve more borrowers, lift conversion rates, and push revenue past $1 billion. For months, executives pointed to AI breakthroughs and raised guidance again and again. But behind the scenes, the lawsuit says that same model was overreacting to macro signals, turning far...Read more

On May 27, 2026, two Co-Lead Plaintiffs were appointed in the class action lawsuit captioned Ortolani v. Plug Power Inc., et al., 1:26-cv-00165-MAD-DJS. United States Magistrate Judge in the Northen District of New York, Daniel Stewart, signed the order that also approved Levi & Korsinsky, LLP and Pomerantz LLP as Co-Lead Counsel in the action....Read more

AMENDED SUMMARY NOTICE OF SETTLEMENT Teuza v. Lindon et al., C.A. NO. 2022-0130-BWD (Del. Ch.) The Court of Chancery of the State of Delaware has directed the dissemination of the following Amended Summary Notice for the above-captioned stockholder class action. The full Notice and related documents are available at https://www.bionessstockholdersettlement.com/ . Amended Summary Notice

ImmunityBio told investors it was sitting on a breakthrough. A cancer treatment with massive potential. Even framed as a path toward a cure. But that promise did not match reality. In January 2026, the company’s top executive went on a podcast claiming its drug Anktiva could treat all cancers and even prevent cancer. Big statements....Read more

Super Micro told investors it was riding the AI wave. Record demand. Explosive growth. Billions in revenue. But behind the scenes, a very different story was unfolding. Starting in April 2024, the company reported massive sales driven by AI servers and global demand. Executives pointed to strong growth across the U.S. and Asia and kept...Read more

Atara told investors it was on the verge of a breakthrough. A first of its kind cancer therapy. Strong data. FDA approval in sight. But behind the scenes, serious problems were building. In May 2024, Atara submitted its FDA application, claiming promising trial results and a smooth path forward. By July, the FDA granted priority...Read more

Coty told investors a comeback was already underway. Growth was coming back. Profits were set to rebound. Everything looked on track. But behind the scenes, key parts of the business were already under pressure. In November 2025, Coty promised improving sales, strong fragrance demand, and a return to growth by the second half of 2026....Read more